PRESERVE-006 Phase 1 Trial Results: Gotistobart (BNT316/ONC-392) and 177Lu Combination Shows Promise for mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxVIOLET Phase 1/2 Trial Final Results: 161Tb-PSMA-I&T Shows Promising Results
/in Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 Trial of Novel Radioligand Therapy 177Lu-JH020002 Shows Promise
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 Results for MHB088C Antibody-Drug Conjugate for mCRCP
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1 Trial: APG-5918 an EED Inhibitor for Prostate Cancer Therapy
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: CTS2190 Targets Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- Phase 2 ARTEMIS-003 Trial: HS-20093 for mCRPC April 30, 2026
- B7-H3 Emerges as Prime Target for Prostate Cancer Across All Stages April 30, 2026
- Phase 1 Study of BPX-601: A Controlled Immune Therapy for Advanced Prostate Cancer April 29, 2026
- Drugging the Undruggable: Million-Fold Leap Targets Prostate Cancer’s Elusive Androgen Receptor April 28, 2026